Insulet Corp (PODD)

Insulet Corp is trading at $146.79, down 0.90% on the session. The 50 day average sits at $140.43 and the 200 day at $185.76, which puts the stock in a downtrend. RSI is at 55.6, which reads as strong, and MACD is bullish crossover. Volume is average.

The nearest support is around $140.98 with resistance near $143.45, so that band frames the current range. Average daily movement is roughly $4.52, or about 3.1% of the share price, which is what any stop placement has to allow for. The overall health score of 54 out of 100 combines a trend score of 23, momentum of 76 and a risk score of 71.

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.